Shots:

• SpringWorks to receive $35M as upfront and $ 375M as clinical- regulatory- and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to get an exclusive license of all assets relating to the FAAH inhibitor program including PF-04457845
• The acquisition magnifies Jazz's neuroscience pipeline into a new disease area- further optimizes SpringWorks' strategic focus on targeted oncology
• Jazz will initially focus on developing PF-04457845 as a treatment in PTSD for patients with inadequate response to currently approved therapies

 ­ Ref: PRNewswire | Image: Spring Works